The endocrine neoplasia syndromes are a group of disorders characterised by tumours of one or more endocrine gland.
Multiple Endocrine Neoplasia type 1 is characterised by the triad of parathyroid hyperplasia, pancreatic endocrine tumours and pituitary adenomas.
Multiple Endocrine Neoplasia type 4 is an autosomal dominant disorder characterized by the presence of parathyroid and pituitary tumours in addition to other malignancies.
The spectrum of CDC73-related disorders includes Hyperparathyroidism-jaw tumour syndrome, characterised by primary hyperparathyroidism in late adolescence or early adulthood with some patients developing ossifying fibromas of the mandible or maxilla, Parathyroid carcinoma and Familial Isolated Hyperparathyroidism.
Familial Isolated Pituitary Adenoma (FIPA) is characterised by early-onset disease, often aggressive tumour growth and a predominance of somatotroph and lactotroph adenomas.
Multiple Endocrine Neoplasia type 2A (MEN2A) is diagnosed clinically by the occurrence of two or more specific endocrine tumours: medullary thyroid carcinoma (MTC), phaeochromocytoma, or parathyroid adenoma/hyperplasia.
Multiple Endocrine Neoplasia type 2B (MEN2B) is characterised by the presence of mucosal neuromas of lips and tongue as well as distinctive facies with enlarged lips, a ‘marfanoid’ body habitus and medullary thyroid cancer.
Patients with Familial Medullary Thyroid Cancer (FMTC) have medullary thyroid cancer (MTC) without additional MEN2A or MEN2B-related features.
More information
Test code
R217 Multiple endocrine neoplasia type 1 & R218 Multiple endocrine neoplasia type 2.
Eligibility
Eligibility criteria for genomic tests can be found in the National Genomic Test Directory.
This lists the clinical specialties that would be expected to request for a given clinical indication and sets out which patients should be considered for testing.
Test order form
All samples for genomic testing should be accompanied by a fully completed request form.
The request form should include as much clinical information about the patient or family member, family relationships and the requested test code (R number). All request forms must indicate either a specific disorder/gene(s) to be investigated or, a request to extract and store DNA.
This form should be used for the majority of test requests.
Please do not download and store this on your desktop or system. The form is regularly updated. Our recommendation is to save or bookmark a link to our website to ensure you are working with the most up-do-date version.
Consent
An appropriate discussion of genomic testing and the possible implications for a patient and their family members must take place before testing is requested.
It is the referring clinician’s responsibility to ensure that the patient/carer knows the purpose of the test and that the sample may be stored for future diagnostic testing. In submitting a sample with a request form, the clinician confirms that informed consent has been obtained for (a) testing and storage (indefinitely) (b) the use of this sample and the information generated from it to be shared with members of the donor’s family and their health professionals (if appropriate). The patient should be advised that the samples may be used anonymously for quality assurance and training purposes.
If stated as a requirement for a specific test, a record of this discussion must be retained within the patient record when a genomic test is ordered.
For more information please view the Consent and Confidentiality in Genomic Medicine guidelines from the Joint Committee on Medical Genetics.
Samples and transport
Before sending samples for genomic testing, please ensure you follow the correct preparation and transport guidelines. This includes information on sample types, volumes, handling, labelling, and packaging standards.
For a full list of sample requirements and transport guidance, please visit the samples and transport page of the website.
Results and turnaround times
Turnaround times (TATs) for genomic tests are continually refined through ongoing reviews of testing standards.
Results will be returned to the email account or clinician listed on the request form.
Visit the results and turnaround page for more information.
The laboratory participates in the European Molecular Genetics Quality Network (EMQN) sequencing scheme.